Visibility into Value Creation and Capture for Trials Site Owners
Our December Trials Sites Snapshot provides easily digestible information for owner-operators, including: Founders Advisors’ market commentary Public market metrics/KPIs Recent M&A activity Recommended reading Access the report here and reach out to Courtney Davies or Michael White if you would like to have a more individualized conversation about market dynamics and valuation drivers for your…
Our Clinical Trials Site Value Driver Report highlights the key factors that drive valuation for independent clinical trials site businesses. It breaks down the most important qualitative and quantitative value drivers: Qualitative Drivers: depth and pipeline of principal investigators; a reliable patient enrollment strategy; a clear therapeutic-area strategy (either niche or diversified); a strong, energetic management team; independence from…
Our latest webinar offered a clear, straightforward overview of what it means for healthcare and life sciences companies to partner with private equity. Led by Michael White, the session walked through what PE buyers look for, how businesses are valued, and what business owners should expect in a sale or partnership process. During the webinar,…
Michael has devoted his career to pharma services. He has served as an M&A advisor to some of the world’s leading companies in the sector, including ICON, WIL Research (now Charles River), Cambrex, Lilly, Abbott, Gilead Sciences and Fujirebio, among others. In addition to M&A advisory, Michael served as CFO of Carbylan Therapeutics, guiding the company through a Phase III clinical trial and successful IPO. Upon bringing his deep pharma services expertise to the lower middle market, Michael rapidly emerged as a leading advisor to owners of privately held pharma services companies, guiding them through scaling, exit planning and securing institutional investments/partnerships.
Courtney is a trusted resource for pharma services and clinical trial site owner-operators. Her clients depend on her to navigate growth, partnership and succession/exit strategies. With a background in investment banking and private equity, Courtney brings analytical acumen and deep sector expertise to her clients, along with grit and determination garnered from running cross county in college. Courtney has managed sale/partnership processes on behalf of owners of clinical trials sites and other outsourced service providers selling into blue chip pharma. She regularly authors and publishes research in the sector.
Thomas Dixon is a healthcare strategist and M&A executive. Having served as a development officer at four distinct, PE-backed portfolio companies, he helps pharma services business owners in the lower middle market gain insight into how institutional investors think. From past experiences in consulting and industry, Thomas has deep expertise in multiple clinical service lines, including women’s health, aesthetics/cosmetics, surgery, neurosciences and cardiovascular. Thomas is known for his creative, candid approach to serving and advising his clients.
Bluegrass Pharmacy acquired by WellPartner
Allervie Health has been acquired by Summit Partners.
AmeriPac has been acquired by Veritiv Corporation.
DermLab has been acquired by PathGroup.